Last reviewed · How we verify

Doxycycline and Rifampin

University of South Florida · Phase 3 active Small molecule

Doxycycline and Rifampin is a Antibiotic combination Small molecule drug developed by University of South Florida. It is currently in Phase 3 development for Investigational combination therapy for bacterial infections (specific indication under phase 3 evaluation not publicly detailed). Also known as: Atridox and Rifadin.

Doxycycline and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections.

Doxycycline and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections. Used for Investigational combination therapy for bacterial infections (specific indication under phase 3 evaluation not publicly detailed).

At a glance

Generic nameDoxycycline and Rifampin
Also known asAtridox and Rifadin
SponsorUniversity of South Florida
Drug classAntibiotic combination
TargetBacterial 30S ribosome (doxycycline); bacterial RNA polymerase (rifampin)
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

Doxycycline is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Rifampin inhibits bacterial RNA polymerase, blocking transcription. Together, this combination provides broad-spectrum antimicrobial activity against various pathogens, potentially including intracellular bacteria.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Doxycycline and Rifampin

What is Doxycycline and Rifampin?

Doxycycline and Rifampin is a Antibiotic combination drug developed by University of South Florida, indicated for Investigational combination therapy for bacterial infections (specific indication under phase 3 evaluation not publicly detailed).

How does Doxycycline and Rifampin work?

Doxycycline and rifampin are a combination of two antibiotics that work synergistically to inhibit bacterial protein synthesis and RNA polymerase, respectively, to treat infections.

What is Doxycycline and Rifampin used for?

Doxycycline and Rifampin is indicated for Investigational combination therapy for bacterial infections (specific indication under phase 3 evaluation not publicly detailed).

Who makes Doxycycline and Rifampin?

Doxycycline and Rifampin is developed by University of South Florida (see full University of South Florida pipeline at /company/university-of-south-florida).

Is Doxycycline and Rifampin also known as anything else?

Doxycycline and Rifampin is also known as Atridox and Rifadin.

What drug class is Doxycycline and Rifampin in?

Doxycycline and Rifampin belongs to the Antibiotic combination class. See all Antibiotic combination drugs at /class/antibiotic-combination.

What development phase is Doxycycline and Rifampin in?

Doxycycline and Rifampin is in Phase 3.

What are the side effects of Doxycycline and Rifampin?

Common side effects of Doxycycline and Rifampin include Photosensitivity, Gastrointestinal upset, Hepatotoxicity, Drug interactions.

What does Doxycycline and Rifampin target?

Doxycycline and Rifampin targets Bacterial 30S ribosome (doxycycline); bacterial RNA polymerase (rifampin) and is a Antibiotic combination.

Related